p53 and PCNA Coexpression of 81 Pleural and Peritoneal Effusion Specimens: An Immunohistochemical Study

El-Habashi, Ahmed; Freeman, Scott; B, el-Morsi; Morris, Gilbert F.; Marrogi, Aizen J.

doi:10.1016/s0344-0338(96)80057-4

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…p53 and PCNA immunoreactivity correlated strongly, and co-expression was suggested to represent a significant indicator for malignancy. 111 In another study of 154 body fluids, 3 of 121 (2.5%) benign samples were p53-positive compared to 7 of 16 malignant fluids (43.7%) and 4 of 17 suspicious fluids (23.5%). 112 p53 immunostaining of 103 cell blocks from pleural effusions was performed (monoclonal Ab BP53-12).…”

Section: Body Cavity Effusionsmentioning

confidence: 94%

Evaluation of apoptosis in cytologic specimens

Shtilbans¹,

Burstein

2010

Diagnostic Cytopathology

View full text Add to dashboard Cite

A hallmark of neoplasia is dysregulated apoptosis, programmed cell death. Apoptosis is crucial for normal tissue homeostasis. Dysregulation of apoptotic pathways leads to reduced cytocidal responses to chemotherapeutic drugs or radiation and is a frequent contributor to therapeutic resistance in cancer. The literature pertaining to detection of apoptotic pathway constituents in cytologic specimens is reviewed herein. Virtually all methods for detecting apoptosis, including classic cytomorphologic evaluation, TUNEL assay, immunocytochemistry, and gene sequence analysis, may be applied to cytologic samples as well as tissue. Components of both intrinsic and extrinsic apoptotic pathways have been studied, including many reports examining p53 and bcl-2, as well as studies of caspase inhibitory proteins XIAP and survivin, death receptors and ligands such as Fas, Fas-ligand, and TRAIL. p53 undergoes oncogenic alteration more than any other protein; its immunocytochemical detection almost always connotes loss of its physiologic role as an inducer of apoptosis in response to a damaged genome. Several reports establish cytologic sampling as being as useful as tissue sampling. In one respect cytologic sampling is superior to tissue sampling in particular, by allowing clinicians to repeat sampling of the same tumor before and after administration of therapy; a number of reports use this approach to attempt to predict tumor response by assaying the effect of chemotherapy on the induction of apoptosis.

show abstract

Section: Body Cavity Effusionsmentioning

confidence: 94%

Evaluation of apoptosis in cytologic specimens

Shtilbans¹,

Burstein

2010

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…The average Ki-67 counts for benign, malignant diploid and malignant aneuploid effusions were 11, 19, and 35, respectively. Proliferating cell nuclear antigen (PCNA) counts were found to be significantly higher in malignant effusions (p < 0.001), when compared to benign ones in a study of 87 effusions [172]. Three studies of nucleolar organizer regions (AgNOR) have found this method beneficial in the differentiation of benign mesothelium from malignant cells [173][174][175].…”

Section: Proliferation Markersmentioning

confidence: 99%

Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature¹

Davidson

2001

Analytical Cellular Pathology

View full text Add to dashboard Cite

Carcinoma of the ovary is the leading cause of death from gynecological cancer in western countries. Ovarian carcinoma is commonly associated with the accumulation of fluid containing malignant cells in the peritoneal, and not infrequently in the pleural cavity. The differentiation of these cells from reactive mesothelial cells is at times difficult. In addition, tumor progression in ovarian carcinoma and the biological characteristics of carcinoma cells in effusions compared to their counterparts in solid tumors are poorly understood. This review details the current knowledge regarding diagnostic and biologic aspects of effusion cytology, with emphasis on ovarian carcinoma. Results from our first studies of effusions are subsequently presented. These attempt to address several issues. First, to improve the diagnostic ability to detect cancer cells in effusions using antibodies designed for the differentiation of epithelial cells from mesothelial cells. Secondly, to study genotypic and phenotypic differences between ovarian carcinoma cells in effusions, solid primary tumors and metastatic lesions, as well as to compare malignant cells in peritoneal and pleural effusions. These studies of carbohydrate antigens, E‐cadherin complex and matrix metalloproteinases (MMP) attempted to evaluate whether ovarian carcinoma cells in effusions possess true metastatic properties, or are similar to the cells in primary tumors, thereby merely representing the result of a shedding process. Finally, the prognostic role of these molecules was studied in solid tumors from a patient cohort consisting of long‐ and short‐term survivors, followed for up to 20 years. Figure 1 on http://www.esacp.org/acp/2001/23‐3,4/davidson.htm.

show abstract

“…The same team studied the correlation of mutant p53 immunostaining and proliferative index in 81 cases of pleural and peritoneal effusions. p53 and PCNA immunoreactivity correlated strongly, and co‐expression was suggested to represent a significant indicator for malignancy 111. In another study of 154 body fluids, 3 of 121 (2.5%) benign samples were p53‐positive compared to 7 of 16 malignant fluids (43.7%) and 4 of 17 suspicious fluids (23.5%) 112…”

Section: Apoptosis In Cytological Specimens From Specific Tissuesmentioning

confidence: 96%

Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

Thiéblemont

Antal

Lacotte‐Thierry

et al. 2005

Cancer

View full text Add to dashboard Cite

A hallmark of neoplasia is dysregulated apoptosis, programmed cell death. Apoptosis is crucial for normal tissue homeostasis. Dysregulation of apoptotic pathways leads to reduced cytocidal responses to chemotherapeutic drugs or radiation and is a frequent contributor to therapeutic resistance in cancer. The literature pertaining to detection of apoptotic pathway constituents in cytologic specimens is reviewed herein. Virtually all methods for detecting apoptosis, including classic cytomorphologic evaluation, TUNEL assay, immunocytochemistry, and gene sequence analysis, may be applied to cytologic samples as well as tissue. Components of both intrinsic and extrinsic apoptotic pathways have been studied, including many reports examining p53 and bcl‐2, as well as studies of caspase inhibitory proteins XIAP and survivin, death receptors and ligands such as Fas, Fas‐ligand, and TRAIL. p53 undergoes oncogenic alteration more than any other protein; its immunocytochemical detection almost always connotes loss of its physiologic role as an inducer of apoptosis in response to a damaged genome. Several reports establish cytologic sampling as being as useful as tissue sampling. In one respect cytologic sampling is superior to tissue sampling in particular, by allowing clinicians to repeat sampling of the same tumor before and after administration of therapy; a number of reports use this approach to attempt to predict tumor response by assaying the effect of chemotherapy on the induction of apoptosis. Diagn. Cytopathol. 2010;38:685–697. © 2010 Wiley‐Liss, Inc.

show abstract

p53 and PCNA Coexpression of 81 Pleural and Peritoneal Effusion Specimens: An Immunohistochemical Study

Cited by 5 publications

References 28 publications

Evaluation of apoptosis in cytologic specimens

Evaluation of apoptosis in cytologic specimens

Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature¹

Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

Contact Info

Product

Resources

About

p53 and PCNA Coexpression of 81 Pleural and Peritoneal Effusion Specimens: An Immunohistochemical Study

Cited by 5 publications

References 28 publications

Evaluation of apoptosis in cytologic specimens

Evaluation of apoptosis in cytologic specimens

Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature1

Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

Contact Info

Product

Resources

About

Ovarian Carcinoma and Serous Effusions. Changing Views Regarding Tumor Progression and Review of Current Literature¹